GlaxoSmithKline plc (GSK)

NYSE - NYSE Real Time Price. Currency in USD
40.68-0.45 (-1.09%)
At close: 4:02 PM EDT
People also watch:
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
Prev Close41.13
Bid40.67 x 11500
Ask40.68 x 2200
Day's Range40.65 - 41.02
52wk Range37.82 - 45.58
1y Target EstN/A
Market Cap101.89B
P/E Ratio (ttm)2,542.50
Avg Vol (3m)2,688,369
Dividend & Yield1.87 (4.54%)
Earnings DateN/A
Trade prices are not sourced from all markets
  • The Wall Street Journal17 minutes ago

    [$$] Novartis Profit Helped by GlaxoSmithKline Joint Venture

    Novartis said net income increased in the third quarter thanks to proceeds from its consumer health joint venture with GlaxoSmithKline, helping to offset declining revenue and heavy investment in its new ...

  • American City Business Journals17 hours ago

    GlaxoSmithKline seeking U.S. approval for shingles vaccine

    GlaxoSmithKline said Monday it has submitted a biologics license application with the Food and Drug Administration seeking approval for its experimental shingle vaccine. Analysts have projected the new drug candidate, called Shingrix, could develop into a $1 billion a year product — if it receives regulatory approval. Shingles is an acute and painful inflammation of nerve cells that occurs as a result of reactivation of latent chickenpox virus.

  • Reutersyesterday

    GSK files potential $1 bln shingles vaccine for U.S. approval

    GlaxoSmithKline has filed its shingles vaccine Shingrix for U.S. regulatory approval, the drugmaker said on Monday, bringing the potential $1 billion-a-year seller a step closer to market. Shingrix is viewed by analysts as among the British company's most promising experimental products, since it has shown greater protection among older recipients than Merck & Co's rival shot Zostavax. The company, which will see Emma Walmsley take over as chief executive in 2017, is seeking to revitalise a drug portfolio hit by falling sales of best-selling inhaled lung treatment Advair.